NASDAQ$CYTK

Cytokinetics Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Cytokinetics reported Q4 2025, revenue of $17.8M, net loss of $183M, diluted EPS of $-1.50.

For Q4 2025, Cytokinetics reported revenue of $17.8M, a net loss of $183M, diluted EPS was $-1.50. Management discusses segment performance, capital allocation, and outlook in the earnings release.

  • Revenue $17.8M.
  • Net loss $183M.
  • Diluted EPS $-1.50.

Headline financials

Total Revenue

$17.8M

Previous: $16.9M+5.2%
EPS (adj)

-$1.50

Previous: -$1.26-19.0%
R&D Expenses

$104M

Previous: $93.6M+11.5%
G&A Expenses

$91.7M

Previous: $62.3M+47.1%
Net Cash Utilization

$134M

No prior period
Net Income

-$183M

Previous: -$150M-22.0%
Operating Income

-$178M

Previous: -$139M-28.3%

Revenue & EPS history

Cytokinetics · Revenue · Quarterly

$17.8M

Q4 2025+5.2%vs Q4 2024
Beat estimate in 4 of 15 quarters(27%)
ActualEstimate

Forward guidance

The release discusses Cytokinetics's outlook for upcoming periods, including capital allocation, operating priorities, and market risks, without relying solely on numeric EPS bridges.

Tailwinds

  • Cytokinetics cites operational execution and demand trends supporting the outlook.
  • Balance sheet and liquidity actions aim to fund growth and returns.

Headwinds

  • GAAP profitability remained under pressure in Q4 2025.
  • Macro, pricing, and input-cost volatility could pressure margins.
  • Segment mix and one-time items may affect quarter-to-quarter comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+0.4%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+2.2%

Avg return

30 days after

49%

32 / 65 earnings

Positive

+21.4%

Q4 2014

Best reaction

-17.7%

Q2 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+16.8%+16.5%+9.5%
Q4 2025-10.3%-12.4%-10.8%
Q3 2025+1.9%+12.4%+10.9%
Q1 2025-2.8%-5.4%-4.9%
Q4 2024-3.1%-7.5%-9.0%
Q3 2024+6.3%+11.6%-3.0%
Q2 2024+8.9%+9.5%+5.6%
Q1 2024-1.9%-11.3%-19.1%
Q4 2023-7.5%-6.4%-11.3%
Q3 2023+3.5%+2.1%-4.4%
Q2 2023+6.8%+2.8%+15.8%
Q1 2023+0.3%-1.3%-1.8%
Q4 2022-8.7%-9.8%-18.8%
Q3 2022-9.8%-8.6%-3.3%
Q2 2022+21.0%+22.5%+26.2%
Q1 2022+0.9%-12.6%+7.2%
Q4 2021+11.7%+14.7%+16.3%
Q3 2021+12.4%+18.2%+2.4%
Q2 2021+7.8%+8.2%+10.0%
Q1 2021+2.8%+0.8%-13.4%
Q4 2020-9.7%-6.4%+15.0%
Q3 2020+5.1%+0.8%+2.4%
Q2 2020-2.8%-4.7%+2.2%
Q1 2020-4.2%+27.8%+23.3%
Q4 2019+4.4%+1.1%-15.4%
Q3 2019-5.5%-6.5%-18.3%
Q2 2019+1.1%-2.0%+5.5%
Q1 2019+12.6%+16.7%+10.4%
Q4 2018-0.8%-2.7%+19.2%
Q3 2018+10.6%+5.7%+17.5%
Q2 2018-5.7%-7.0%-9.5%
Q1 2018+19.3%+14.5%+21.4%
Q4 2017-10.8%-13.9%-2.8%
Q3 2017+6.7%+2.2%-43.1%
Q2 2017-5.6%-11.2%+3.1%
Q1 2017-3.0%-7.7%-16.6%
Q4 2016-1.7%-9.2%+8.3%
Q3 2016+9.3%+6.6%+39.7%
Q2 2016+7.3%+12.8%+18.1%
Q1 2016+3.3%
Q4 2015-3.3%
Q3 2015+13.3%
Q2 2015-17.7%
Q1 2015-15.7%
Q4 2014+21.4%
Q3 2014-1.0%
Q2 2014-1.2%
Q1 2014-9.5%
Q4 2013+0.5%
Q3 2013+0.0%
Q2 2013-7.2%
Q1 2013-1.6%
Q4 2012-1.0%
Q3 2012-1.6%
Q2 2012+6.3%
Q1 2012-4.0%
Q4 2009+0.8%
Q4 2011+0.8%
Q3 2011+3.5%
Q2 2011-14.0%
Q4 2010-14.0%
Q1 2011+2.9%
Q3 2010-4.0%
Q2 2010-14.3%
Q1 2010+0.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro